Openbookopenbook
Equity
Basilea Pharmaceutica AG(0QNA)
GBP --+0.00%
Reward80High
Risk14Low
📊75%Data
Strong 17% profit margin
0QNA
+0.0 · +0.00%
GBP · LSE
Basilea Pharmaceutica AG |
Quality Compounder
Market Cap:571.65M
ℹ️
Reward Rating
80
High
Top 5% (model universe)
75% data coverage
ℹ️
Risk Rating
14
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0QNA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Basilea Pharmaceutica AG?

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.

0QNA · Verdict

Strong reward · low risk

0QNA scores well on profitability and cash flow with no major weaknesses flagged in the model.

Based on 88% data coverage

0QNA · Verdict

What’s working & what to watch

Strengths 6

  • Profitability98/100

    17% net margin · 39% ROE

  • Cash flow94/100

    26% free-cash-flow margin

  • Balance sheet93/100

    Net debt/EBITDA 1.4×

  • Growth91/100

    Rev +16.3% CAGR · earnings +49.0%

  • Volatility80/100

    Top decile vs peers

  • Valuation75/100

    Above average

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Basilea Pharmaceutica AG?

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company is listed on the LSE in UK, with a market capitalisation of 571.65M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: High (80)

The scoring profile indicates a strong reward potential, driven primarily by profitability and growth. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market Cap571.65M
P/E RatioN/A
Dividend YieldN/A
52 Week High59.55
52 Week Low43.2
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares Outstanding11M
No. of Employees189
IndustryN/A
ExchangeLSE
Beta0.425
CurrencyGBP
Websitewww.basilea.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.